Search Results
Dec 02, 2025, 07:53 ET Cosmo und Glenmark geben die Marktzulassung von Winlevi® (Clascoteron) 10 mg/g Creme zur Behandlung von Akne in 17 Ländern in Europa bekannt
ist ein Biowissenschaftsunternehmen mit Schwerpunkt auf MedTech AI, Dermatologie, Magen-Darm-Erkrankungen sowie Auftragsentwicklung und -herstellung (CDMO). Wir entwerfen, entwickeln und produzieren fortschrittliche Lösungen, die den kritischen medizinischen Bedürfnissen gerecht werden und den Pflegestandard
More news about: Glenmark Pharmaceuticals
Dec 02, 2025, 07:31 ET Cosmo et Glenmark annoncent l'autorisation de mise sur le marché de Winlevi® (clascotérone) 10 mg/g, crème pour le traitement de l'acné dans 17 pays d'Europe
spécialisée dans l'IA MedTech, la dermatologie et les maladies gastro-intestinales, et une organisation de développement et de fabrication sous contrat (CDMO). Nous concevons, développons et fabriquons des solutions avancées qui répondent à des besoins médicaux essentiels et améliorent la qualité des soins.
More news about: Glenmark Pharmaceuticals
Dec 02, 2025, 06:42 ET Prefilled Syringes (PFS) Market Size to Grow USD 32.98 Billion by 2035 at a CAGR 13.75 | Vantage Market Research
vaccine demand (influenza, COVID boosters, RSV, pediatric immunization) driving large-volume procurementExpansion of contract manufacturing (CMO/CDMO) for high-volume sterile productionWhy the Prefilled Syringes Market Is a Strategic Imperative for CEOs & CXOsBiologics
More news about: Vantage Market Research
Dec 02, 2025, 03:46 ET WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority
manufacturing, empowering the development of next-generation ADCs through diverse innovative conjugation technologies. Its subsidiary WuXi Vaccines, is a leading CDMO that focuses on vaccine and preventive antibody's development and manufacturing.WuXi Biologics regards sustainability as the cornerstone of long-term
More news about: WuXi Biologics
Dec 01, 2025, 14:31 ET Cosmo y Glenmark anuncian la autorización de comercialización de Winlevi®
ciencias de la vida centrada en la IA de MedTech, la dermatología, las enfermedades gastrointestinales y el desarrollo y fabricación por contrato (CDMO). Diseñamos, desarrollamos y fabricamos soluciones avanzadas que abordan necesidades médicas críticas y elevan la calidad de la atención. Nuestras tecnologías
More news about: Glenmark Pharmaceuticals
Dec 01, 2025, 12:47 ET Next-Generation Biologics and Biosimilars Market to Hit 251.13 billion Dollars by 2033 - Strategic Revenue Insights (SRI)
https://www.strategicrevenueinsights.com/industry/biologics-cdmo-market
More news about: Strategic Revenue Insights
Dec 01, 2025, 10:00 ET UPSHER-SMITH LAUNCHES KYMBEE™ (DEFLAZACORT) TABLETS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet
More news about: Upsher-Smith Laboratories, LLC
Dec 01, 2025, 09:34 ET Cosmo and Glenmark Announce Market Authorisation of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 17 countries in Europe
CosmoCosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted
More news about: Glenmark Pharmaceuticals
Dec 01, 2025, 09:31 ET Cosmo and Glenmark Announce Market Authorisation of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 17 countries in Europe
CosmoCosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted
More news about: Glenmark Pharmaceuticals
Nov 28, 2025, 08:00 ET BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough
a significant R/M NPC therapeutic advancement.Further reinforcing its industry leadership, BioDlink was named Biologics CDMO of the Year at the Biologics CDMO Excellence Europe 2025 awards, recognized for its overall excellence in biologics across core customer needs, including quality,
More news about: BioDlink Biopharm Co., Ltd.
Nov 27, 2025, 10:50 ET Piramal Pharma Solutions obtient la conformité réglementaire pour les impuretés de nitrosamine
27 novembre 2025 /PRNewswire/ -- Piramal Pharma Solutions, organisation mondiale de développement et de fabrication sous contrat (CDMO) de premier plan, qui fait partie de Piramal Pharma Ltd. (NSE : PPLPHARMA) (BSE : 543635), a annoncé aujourd'hui qu'elle avait réussi à se mettre
More news about: Piramal Pharma Solutions
Nov 27, 2025, 10:46 ET Piramal Pharma Solutions erfüllt regulatorische Anforderungen hinsichtlich Nitrosaminverunreinigungen
27. November 2025 /PRNewswire/ -- Piramal Pharma Solutions, eine weltweit führende Auftragsentwicklungs- und Produktionsorganisation (CDMO) und Teil von Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), gab heute bekannt, dass es die Anforderungen hinsichtlich Nitrosaminverunreinigungen
More news about: Piramal Pharma Solutions
Nov 27, 2025, 06:33 ET Piramal Pharma Solutions ottiene la conformità normativa per le impurità nitrosammine
27 novembre 2025 /PRNewswire/ -- Piramal Pharma Solutions, un'organizzazione leader mondiale nello sviluppo e nella produzione su contratto (CDMO) e un'impresa di Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), ha annunciato oggi di avere completato il percorso verso la conformità ai
More news about: Piramal Pharma Solutions
Nov 27, 2025, 06:30 ET Piramal Pharma Solutions logra el cumplimiento normativo para impurezas de nitrosamina
27 de noviembre de 2025 /PRNewswire/ -- Piramal Pharma Solutions, una organización líder mundial en desarrollo y fabricación por contrato (CDMO) y parte de Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), anunció hoy la finalización exitosa de su camino hacia el cumplimiento de los requisitos
More news about: Piramal Pharma Solutions
Nov 26, 2025, 14:19 ET Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities
Nov. 26, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), today announced the successful completion of its journey to compliance with
More news about: Piramal Pharma Solutions
Nov 26, 2025, 14:13 ET Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities
Nov. 26, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), today announced the successful completion of its journey to compliance with
More news about: Piramal Pharma Solutions
Nov 26, 2025, 11:00 ET TCI Biotech Inaugurates Advanced Performance Nutrition Research Center, Expands Into Brain Science to Accelerate Next-Generation Health Innovation
SALT LAKE CITY, Nov. 26, 2025 /PRNewswire/ -- TCI Biotech (TCI Co., Ltd.), a global CDMO+ specializing in functional foods, nutraceuticals, and beauty supplementation, today announced the launch of the TCI Advanced Performance Nutrition
More news about: TCI; TCI Biotech
Nov 26, 2025, 10:00 ET UPSHER-SMITH STRENGTHENS CONNECTIONS WITH THE EPILEPSY COMMUNITY THROUGH AWARENESS, EDUCATION, AND SUPPORT
services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet
More news about: Upsher-Smith Laboratories, LLC
Nov 25, 2025, 09:00 ET Caring Cross and Amrita Research Center Delhi, Amrita Vishwa Vidyapeetham Announce Strategic Partnership to Advance Affordable Cell and Gene Therapies for Underserved Populations Across India
Cross advanced therapy medicinal products are manufactured by Vector BioMed, a for-profit vector contract development and manufacturing organization (CDMO), specializing in rapid lentiviral vector manufacturing solutions to provide the industry with affordable, high-quality GMP lentiviral vectors.For
More news about: Caring Cross
Nov 25, 2025, 05:01 ET Generic Drugs Market Size to Worth USD 898 Billion by 2035, at a CAGR of 5.75% | Research by Vantage Market Research
automation, continuous manufacturing & data integrity toolsExpand licensing, co-marketing, and contract development & manufacturing (CDMO) partnershipsPrioritize regulatory harmonization across FDA, EMA, CDSCO, PMDA & TGATarget growth regions with pharma reforms and
More news about: Vantage Market Research
Nov 24, 2025, 10:47 ET Made Scientific and Cellergy Therapeutics Announce Manufacturing Partnership to Advance First-in-Human Mitochondrial Therapy
/PRNewswire/ -- Made Scientific, Inc., a leading U.S.-based clinical- and commercial-stage cell therapy contract development and manufacturing organization (CDMO), and Cellergy Therapeutics Ltd., a biotechnology company pioneering first-in-class mitochondrial transplantation therapies, today announced a manufacturing
More news about: Made Scientific, Inc.
Nov 24, 2025, 00:12 ET IEI 通過 TFDA 醫療器材品質管理系統查驗，強化醫療設計移轉與量產能力
威強電今日宣布，新北汐止與基隆七堵兩處廠區已通過衛生福利部食品藥物管理署（TFDA）查核並取得品質管理系統（QMS）核可（汐止廠證號：QMS2376、基隆廠證號：QMS2377），同時持續維持 ISO 13485:2016 認證。身為同時具備國內外醫療 QMS 資格的台灣製造商，IEI 協助 OEM／ODM／CDMO 客戶加速法規就緒並在亞洲、 美國與歐洲擴大量產。
More news about: IEI Integration Corp.
Nov 23, 2025, 21:56 ET IEI erhält TFDA-QMS-Zulassung und ISO 13485-Zertifizierung und stärkt damit die auditfähige Fertigung für den Transfer von MedTech-Designs.
taiwanesischen Hersteller, der sowohl über nationale als auch internationale QMS-Zertifizierungen für Medizinprodukte verfügt, ermöglicht IEI seinen OEM-/ODM-/CDMO-Kunden, die regulatorische Bereitschaft zu beschleunigen und die Produktion in Asien, den USA und Europa zu skalieren.
More news about: IEI Integration Corp.
Nov 23, 2025, 21:24 ET Avec l'approbation QMS de la TFDA et la certification ISO 13485 en poche, IEI renforce la fabrication vérifiable pour les transferts de conception medtech
En tant que l'un des fabricants taïwanais détenant des certifications QMS médicales nationales et internationales, IEI permet à ses clients OEM/ODM/CDMO d'accélérer leur préparation réglementaire et d'augmenter leur production en Asie, aux États-Unis et en Europe.
More news about: IEI Integration Corp.
Nov 23, 2025, 21:21 ET IEI obtiene la aprobación del Sistema de Gestión de Calidad de TFDA y la certificación ISO 13485
13485:2016. Como uno de los fabricantes taiwaneses con credenciales de SGC médicas tanto nacionales como internacionales, IEI permite a sus clientes OEM/ODM/CDMO acelerar el cumplimiento normativo y escalar la producción en Asia, Estados Unidos y Europa.
More news about: IEI Integration Corp.